These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 10696996)

  • 1. Angiotensin II receptor antagonists.
    Burnier M; Brunner HR
    Lancet; 2000 Feb; 355(9204):637-45. PubMed ID: 10696996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with angiotensin II antagonists in hypertensive patients.
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S142-6. PubMed ID: 21143288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of angiotensin II antagonists in the treatment of hypertension].
    Gerc V
    Med Arh; 2002; 56(3):167-73. PubMed ID: 12378864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with angiotensin II antagonists in hypertensive patients.
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Clin Exp Pharmacol Physiol Suppl; 1996; 3():S142-6. PubMed ID: 8993854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?
    de Gasparo M; Levens N
    Pharmacol Toxicol; 1998 Jun; 82(6):257-71. PubMed ID: 9677617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure].
    Andersen RS; Christensen S
    Ugeskr Laeger; 2001 Dec; 163(50):7036-9. PubMed ID: 11794033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Various approaches to blockade of the renin-angiotensin system: persistent renin response.
    Brunner HR; Nussberger J; Waeber B
    J Hypertens Suppl; 1990 Dec; 8(7):S149-53. PubMed ID: 2095383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of angiotensin II inhibition in cardiovascular medicine.
    Meier P; Maillard M; Burnier M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):15-30. PubMed ID: 15720221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison with other antihypertensive drugs, especially with ACEI].
    Hiwada K
    Nihon Rinsho; 1999 May; 57(5):1187-93. PubMed ID: 10361454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of antihypertensive therapy: angiotensin II receptor antagonists.
    Ellis ML; Patterson JH
    Pharmacotherapy; 1996; 16(5):849-60. PubMed ID: 8888079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease.
    Saunders E; Gavin JR
    J Clin Hypertens (Greenwich); 2003; 5(1 Suppl 1):12-7. PubMed ID: 12556668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M
    Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.